ID   KTOR1
AC   CVCL_E6D6
RX   PubMed=31900393;
CC   Population: Japanese.
CC   Doubling time: 85.8 hours (PubMed=31900393).
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK; Note=E13A20 v1 fusion (PubMed=31900393).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (PubMed=31900393).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C2926; Lung non-small cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_E6D7 ! KTOR1-RE
SX   Female
AG   29Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=31900393; DOI=10.1038/s41467-019-13771-5; PMCID=PMC6941996;
RA   Tsuji T., Ozasa H., Aoki W., Aburaya S., Yamamoto Funazo T., Furugaki K.,
RA   Yoshimura Y., Yamazoe M., Ajimizu H., Yasuda Y., Nomizo T., Yoshida H.,
RA   Sakamori Y., Wake H., Ueda M., Kim Y.H., Hirai T.;
RT   "YAP1 mediates survival of ALK-rearranged lung cancer cells treated
RT   with alectinib via pro-apoptotic protein regulation.";
RL   Nat. Commun. 11:74.1-74.16(2020).
//